ArticleExperimental neurology2012
Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I?
Article in Experimental neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Metabolic targeting by a small extracellular vesicle-based cellulose-GelMA hydrogel restores neurovascular regeneration in diabetic nerve injury.Bioactive materials · 2027Article
- Review
- Biomarkers and signaling pathways of diabetic nephropathy and peripheral neuropathy: possible therapeutic intervention of rutin and quercetin.Diabetology international · 2024Review
- Ketolysis is required for the proper development and function of the somatosensory nervous system.Experimental neurology · 2023Article
- Ketolysis is Required for the Proper Development and Function of the Somatosensory Nervous System.bioRxiv : the preprint server for biology · 2023Article
- Abnormal Intraepidermal Nerve Fiber Density in Disease: A Scoping Review.medRxiv : the preprint server for health sciences · 2023Article
- Abnormal intraepidermal nerve fiber density in disease: A scoping review.Frontiers in neurology · 2023Article
- Vescalagin from Pink Wax Apple (Plants (Basel, Switzerland) · 2021Article
- Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy.International journal of molecular sciences · 2021Review
- TNF-ɑ Induces Methylglyoxal Accumulation in Lumbar Herniated Disc of Patients With Radicular Pain.Frontiers in behavioral neuroscience · 2021Article
- Metformin: A Prospective Alternative for the Treatment of Chronic Pain.Frontiers in pharmacology · 2020Review
- The Antidepressant-Like Effects of Hesperidin in Streptozotocin-Induced Diabetic Rats by Activating Nrf2/ARE/Glyoxalase 1 Pathway.Frontiers in pharmacology · 2020Article
- Diabetic neuropathy research: from mouse models to targets for treatment.Neural regeneration research · 2019Review
- Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes.Neurobiology of disease · 2019Article
- Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal.Scientific reports · 2019Article
- Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.Acta neuropathologica communications · 2019Article
- Activation of the integrated stress response in nociceptors drives methylglyoxal-induced pain.Pain · 2019Article
- Deletion of the insulin receptor in sensory neurons increases pancreatic insulin levels.Experimental neurology · 2018Article
- Rats bred for low and high running capacity display alterations in peripheral tissues and nerves relevant to neuropathy and pain.Brain and behavior · 2017Article
- Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Diabetic neuropathy is a common complication of diabetes mellitus with over half of all patients developing neuropathy symptoms due to sensory nerve damage. Diabetes-induced hyperglycemia leads to the accelerated production of advanced glycation end products (AGEs) that alter proteins, thereby leading to neuronal dysfunction. The glyoxalase enzyme system, specifically glyoxalase I (GLO1), is responsible for detoxifying precursors of AGEs, such as methylglyoxal and other reactive dicarbonyls. The purpose of our studies was to determine if expression differences of GLO1 may play a role in the development of diabetic sensory neuropathy. BALB/cJ mice naturally express low levels of GLO1, while BALB/cByJ express approximately 10-fold higher levels on a similar genetic background due to increased copy numbers of GLO1. Five weeks following STZ injection, diabetic BALB/cJ mice developed a 68% increase in mechanical thresholds, characteristic of insensate neuropathy or loss of mechanical sensitivity. This behavior change correlated with a 38% reduction in intraepidermal nerve fiber density (IENFD). Diabetic BALB/cJ mice also had reduced expression of mitochondrial oxidative phosphorylation proteins in Complexes I and V by 83% and 47%, respectively. Conversely, diabetic BALB/cByJ mice did not develop signs of neuropathy, changes in IENFD, or alterations in mitochondrial protein expression. Reduced expression of GLO1 paired with diabetes-induced hyperglycemia may lead to neuronal mitochondrial damage and symptoms of diabetic neuropathy. Therefore, AGEs, the glyoxalase system, and mitochondrial dysfunction may play a role in the development and modulation of diabetic peripheral neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.